A COA Is Not a Medical Doctor

Illusions of trust in the gray market peptide world

Part 1: A COA Is Not a Medical Doctor

There’s no contesting the fact that Americans have entered a collective phase of taking our health into our own hands.

This means different things for different people, of course. For the tech founder, it may mean sourcing peptides – among other compounds – from overseas vendors biohacking herself into a state of mental and physical wellbeing (with the venture capitalist and market analyst both close on her heels). For the podcast bro, it may mean sauna reps, cold plunges, and avoiding seed oils. For the MAHA mom, it may mean scouring the house for hidden microplastics and taking up farming so her children only have to drink raw milk. For transhumanists like boomer biotech CEO Martine Rothblatt, it may mean contesting the very notion of a “natural” or “given” body altogether.

But at its base, the popular trend towards healthcare reclamation – aka “sovereign health” or “optimization” in tech and finance spaces – means something fairly simple for a vast cross-section of Americans: we are the experts on our own bodies, and thus in charge of our own treatment. Healthcare has shifted away from the patients-consulting-experts model and towards a patient-as-expert model. That this has coordinated with the rise of peptide-based health protocols should surprise no one: these chains of amino acids are currently the most visible in a series of innovations that combine the powers of scientific empiricism

And now we’ve arrived in the rapidly expanding wellness economy, where healthcare isn’t administered to us after a long and bureaucratic wait. Instead, it’s purchased by us after a process of self-directed research and vetting. By the time we arrive in the virtual doctor’s office – or, as the case may be, at the direct-to-consumer website, the WhatsApp-coordinated group buy – we believe ourselves informed enough about our treatment in order to consent to it. If we couldn’t trust bona fide medical doctors to overcome their confirmation bias – or worse, their loyalties to drug companies – in order to tell us what we actually need to know about our treatments, then why should we pretend that true medical expertise can be sought anywhere outside the realm of our own research? What do the “experts” have, in other words, that we don’t?

The answer is somewhat sobering. It’s not necessarily about a lack of applicable scientific data – though these, too, can be suppressed, as Nick Jikomes reminds us in this excellent essay. The problem is with the consumer experience itself.

Maybe you’ve purchased a used car before, or at the very least walked through a Costco and had the experience of being pitched to about an in-home security system or some sleek looking patio furniture. There’s already been buy-in from you on some level – you need a car, or you’ve come to the Costco to stock up before a party – and the salesperson in your presence is now charged with closing the deal. Their job becomes to persuade you; your job (ideally) becomes to navigate around their persuasion and towards real information – and thus the product(s) best for you. It’s a challenging dance. I know few who’ve mastered it, myself not included.

Now, consider this fact: with the rise of medical consumerism, the medical “expert” has now effectively shifted into the role of medical salesperson.

While Americans have certainly been right to call the healthcare system on its fairly obvious pursuit of profit, this doesn’t mean that healthcare professionals or pharmaceutical reps scurried off with their tails between their legs, or dutifully changed their ways. If anything, the direct-to-consumer healthcare model seems to be encouraging clinicians to lean into it.

Telehealth, Ease of Access, and the Medical Consumer Boom

We’d all like to pretend we enter every sales situation armed with enough information to render ourselves invulnerable, that we’d be able to keep our cool under pressure and resist coercion at all odds. But what if the situation feels like a life-and-death one for us, and the salesperson standing in front of us effectively becomes the gatekeeper of our health? And what if, given the profundity of our distrust, we’re not even interfacing with a doctor or pharmaceutical representative, both of whom are beneficiaries of some degree of regulatory oversight? What if our research has taken us to a Reddit forum and then to a Discord server and then to the Shopify storefront of some dude in China who just wants our money?

“There is a massive assumption out there that if a company has a website, a shopping cart, and a label on the vial, [there’s] some quality standard being met,” writes peptide industry veteran Joe Mars. “Some regulatory body making sure the product is what it says it is. There isn’t.”

Mars warns that while there are plenty of trustworthy and scientifically-minded research peptide vendors out there, the demand for peptides has grown so exponentially that the market has become bloated with scammers. He goes on:

“The people buying [these peptides] have no idea how much risk they’re actually taking on. They see a COA that says 99% purity and they think the product is fully vetted. It’s not. That COA tested the peptide chain. That’s it. It doesn’t tell you about the manufacturing process, the facility conditions, or what else might be in that vial besides the peptide itself…Nobody thinks about that because nobody explains it.”

Mars is referring to the Certificate of Analysis (COA), usually issued by independent chemical testing laboratories like Janoshik or Finnrick, that ascertains the purity and safety of a batch of peptides. Good independent analysis of peptides requires a given vendor to submit their product to a rigorous battery of tests applied frequently, the processes of which I’ll be delving into in this series.

For now, I’m hoping you’ll see the parallel Mars is drawing: in a medical consumerist paradigm where the salesperson has replaced the expert and the patient has already made up her mind, the COA becomes the basis of a sales strategy. And in cases where a given vendor is honest – e.g. is actually testing and verifying their peptides in the interest of consumer safety, has a demonstrated interest in scientific advancements and healthcare applications, isn’t pretending to be anything more medically high-faluting than a vendor with a loyal customer base – the COA is a legitimate method of building trust.

But what about when this isn’t the case? Could the shady vendor potentially weaponize a fabricated COA against unsuspecting consumers? The answer is most likely yes — but how?

Peptide Research, Done Cleanly — Peptide Partners. Independent HPLC/MS, batch COAs, and endotoxin screening to USP <85> validate identity and purity of peptides for research. Browse inventory and view certificates at Peptide Partners.

The Falsified COA

Let’s begin with the most obvious example of bad actor chicanery: the falsified COA.

If you spend any time in peptide-adjacent corners of the internet, you’ll start to notice a peculiar aesthetic uniformity. Crisp PDFs. Lab logos. Lot numbers. HPLC chromatograms with satisfying peaks. Percentages carried out to two decimal places. A signature at the bottom, often difficult to decipher but suggestive of someone in a white coat somewhere far away. It feels scientific. Like something that’s been submitted for regulatory oversight. Most importantly, it feels real.

And this is precisely the point. A falsified COA doesn’t need to be elaborate. In its laziest form, it can just be a Photoshopped version of another vendor’s certificate, with the batch number and company name swapped out. In more sophisticated iterations, it may involve fabricating an entire report format that mimics a reputable lab’s template—Janoshik, for example, or any number of European or Asian analytical testing companies whose branding is publicly available online. Critically, the average consumer has no way of knowing the difference.

Here’s the uncomfortable truth: unless you personally contact the lab listed on the COA and verify that the batch number corresponds to a real submission from that vendor, you are taking the document at face value. You are trusting the PDF because it looks official. You are lulled into trust by a precise-looking set of numbers. But, alas, precision is not the same thing as truth.

This is where the gray market intersects with something much older than peptides: the psychology of trust. We are primed to defer to documents. Stamps, seals, signatures, logos—they’re the cultural artifacts of authority. They soothe the part of us that knows we can’t personally replicate high-performance liquid chromatography in our kitchens. They allow us to believe that someone else has done the due diligence.

And in some cases, someone has. But in others, the COA is functioning less as a scientific record than as a psychological prop. A sort of doctor-without-the-doctor.

Let’s imagine our used car salesman again. He opens the hood and gestures vaguely at the engine. He hands you a maintenance report. He tells you the vehicle was owned by a little old lady who only drove it to church. You do not have the tools to independently verify any of this. What you have is a charming story with narrative coherence.

And in this case, the falsified COA provides narrative coherence. It tells you that this batch was tested and it passed. It is 99% pure, “completely safe.” What it doesn’t tell you is whether the vial in your hand bears any relationship to the batch in the PDF. Nor does it tell you whether the test was ever performed. Nor whether the peptide was synthesized in a facility with proper contamination controls, or in a warehouse where quality assurance is a rumor.

And because peptides are frequently purchased for research purposes in legal gray zones, the recourse available to consumers is limited. If you ingest something impure, mislabeled, or contaminated, you may not have a regulatory body to complain to. You may not have a formal paper trail.

The falsified COA, in other words, weaponizes the very mechanism meant to safeguard consumers. It leverages our desire for transparency against us. It allows a vendor to build unearned trust quickly, cheaply, and at scale. And in a market exploding with demand, unearned trust converts to revenue. Confoundingly, we find ourselves face-to-face with the medical charlatan again — just now in PDF form.

The Carry-Over COA

If the falsified COA is a blunt instrument, the carry-over COA is a subtler cudgel.

Here’s how it works: A vendor submits a single batch of a peptide—let’s say BPC-157 or Semaglutide—to an independent lab. The results come back clean. 99% purity. No detectable heavy metals. Chromatogram looks like the textbook picture of Grade-A Product.

Now, that PDF has become a powerful asset. Instead of testing each subsequent batch, the vendor can just continue to attach that same COA—sometimes with the original date intact, sometimes with a quietly updated one—to future inventory. The batch number on the website may change, s will the lot printed on the vial. But curiously – conveniently – the COA remains the same.

Peptide synthesis is not a static process. Raw materials vary, as do manufacturing partners and shipping conditions. Even reputable labs can produce inconsistent outputs depending on scale, oversight, and economic pressure. A peptide that tested at 99% purity six months ago tells you very little about the peptide sitting in your mailbox today—unless it’s been tested again.

Imagine trying to scale your business to meet the unrivaled market demand for peptides. To submit each batch to be independently tested and verified safe is absolutely the right thing to do. Given the potential harms posted by heavy metals and endotoxins, the stakes are quite literally life and death: these compounds are about to cross paths with human beings, whether in a lab setting, a clinical setting, or otherwise. But then submitting each batch to be tested is expensive. It eats into margins and requires a good deal of logistical coordination and time. And of course there’s always the possibility that any given batch will turn up contaminated, and you’ll have to do the right thing and throw it out – money down the drain, and all in the name of safety!

In a booming market where customers are often more concerned with price and speed than documentation minutiae, the incentive to cut this corner is obvious and probably quite appealing to the bad-acting vendor who’d rather not concern themselves with the ethics of what they’re doing, nor the gravity of imperiling customers’ health for their personal profit. And because most consumers desperate for a product that they feel will revolutionize their lives are unlikely to scrutinize a given COA for dates or batch alignment, the practice can persist frictionlessly.

If you happen to have a COA on hand, look closely at it. You may notice at least one of the following:

• The test date predates the supposed manufacturing date of your peptides’ batch.

• The lot number on the COA does not match the lot number on your vial.

• The report is labeled “sample provided by client,” with no indication of chain-of-custody controls.

These are not necessarily signs of fraud. But they are at the very least signs of slippage.

The carry-over COA exploits the temporal lag between testing and consumption. It relies on the consumer’s assumption that testing is routine rather than occasional. It banks on the fact that few people understand what “per-batch testing” actually entails, or why it matters. In pharmaceutical manufacturing – a realm which exists under some form of regulatory oversight – each batch of a drug undergoes rigorous quality control before release. Deviations are documented. Failures trigger investigations. There is an infrastructure of accountability.

In the gray peptide market, that infrastructure is largely absent. So when a vendor reuses an old COA, they’re not exactly inventing data. What they’re doing is allowing past good behavior to stand in for present verification.

Sadly, the human heart doesn’t care about past good behavior! It cares about sustained good behavior. So does the human cardiovascular system – especially when it comes to bacterial endotoxins.

A batch of peptides contaminated with endotoxins, residual solvents, or mis-sequenced amino acids will jeopardize the body regardless of what it says on a PDF. The carry-over COA is dangerous precisely because it maintains the illusion of ethical behavior. After all, the peptide once tested clean. If pressed, the vendor may say he has no reason to believe his supplier to be inconsistent. He may even opine that repeated batch testing is redundant.

But without regulatory oversight or any demonstrable commitment scientific rigor, repeated batch testing is all we’ve got.

Why all of this matters

Perhaps you feel inclined to shrug at this point, throw the DIY self-optimizer to the wolves. Caveat emptor, right? Buyer beware. If you’re ordering research peptides from the Discord server of peppypepper99, a guy you met on some shady corner of WhatsApp, what did you expect?

But this is a callous framing of the situation that manages to dodge the point altogether. Medical consumerism is here to stay. There is a reason this is happening, and a good one. The collective movement toward self-directed care – otherwise known as sovereign health, biohacking, optimization, etc.—isn’t an inherently foolish one. As we’ve seen, it’s a rational response to a healthcare system that has long degraded into disrepair. Americans are tired of “expert-driven” healthcare that’s opaque, paternalistic, profit-driven, exclusive, and profoundly slow. As always, we want agency and access. When viewed from this wide angle, even the desires of gym bros sitting in hyperbaric oxygen chambers come into highly relatable focus: they, too, just want to heal and survive.

And of course, there’s always the chance that the experimental big swings pay off. (If they didn’t, you wouldn’t be reading this newsletter!) Sometimes self-directed research produces meaningful improvements in chronic pain, metabolic dysfunction, mood disorders, recovery timelines. The problem arises when agency outruns information, and empirical science becomes more inconvenience than guidepost.

Put another way: sovereignty without complete transparency is theater. We imagine we’ve taken control of our health only to find ourselves right back at square one, staring into the face of yet another profit-seeking pseudo-medical juggernaut.

If you’re going to assume the role of medical decision-maker in your own life, you need data that is at least as rigorous as the data you would demand from a clinician. You need to know not just that a peptide can work in theory, but that the vial in your hand contains what it purports to contain. Otherwise – and this is crucial to understand – your care is not self-directed. You are the non-consensual experimental group in a study that doesn’t exist, and never will.

The falsified COA and the carry-over COA both undermine the foundational premise of sovereign health: that we are choosing a certain product in full cognizance of what we’re getting.

When a vendor fabricates a certificate, they aren’t just committing a petty act of fraud. They are stripping consumers of the ability to consent meaningfully. When a vendor reuses an old COA, they are asking you to trust continuity where there may be none.

You’ll learn a bit more about what informed consent means as you read this series, but suffice to say it’s far more than a bureaucratic hoop to be dodged by some dude with a Shopify storefront. It’s one of the foremost ethical principles of medicine. It’s what we sense is being sacrificed when a doctor begins pitching us on a hot new pharmaceutical drug he’s essentially being paid to push as opposed to honestly assessing our best treatment protocol. And without access to the lab conditions required to ascertain the best possible treatment protocols, we average Americans risk having our pursuit of better health hijacked by a variety of self-interested charlatans, both with and without medical degrees.

Of course this doesn’t mean that the road to self-directed care need be forever obstructed by grifters, nor that our only viable option is to retrace our steps back in the direction of a traditional healthcare model we’ve long since come to distrust. What it means is that our capacity for discernment must evolve alongside our tools for self-optimization.

This is a process that can begin simply enough at the consumer level. For instance: a self-optimizer considering a peptide purchase might do well to ask for batch-specific COAs. She ought to check dates and verify lot numbers, contact labs whenever possible. Educate herself on which tests were run and which were not. Recognize that a purity percentage does not equal sterility, and sterility does not equal safety under all conditions. In other words, she can exercise her right as a consumer to demand the information that actually undergirds her autonomy.

The promise of sovereign health is not that we no longer need experts. It is that we become literate enough in the systems around us to recognize when expertise is genuine and when it’s being simulated. To this end, a COA can either be a trust-building bridge between vendor and consumer, or a means of disambiguating an investment in science from an investment in sales.

The difference between the two hinges not just upon the integrity of the vendor, but upon the vigilance – and exercised discernment – of the consumer. Which means that it’s time for all of us to get better acquainted with the science behind our self-directed care.

Next week in Part 2: we’ll dive deeper into what COAs are actually testing, and informed consent in self-directed healthcare.